Proceed with Caution: Off-label Ketamine Treatment for Major Depressive Disorder

Current Psychiatry Reports

Volumn 16, Issue 12, 2014, Pages

  Sisti, Dominic ^a   Segal, Andrea G ^a   Thase, Michael E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Consent; Depression; Ethics; Ketamine; Safety

Indexed keywords

ETOMIDATE; KETAMINE; THIOPENTAL; TRIAZOLAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANTEROGRADE AMNESIA; ANXIETY DISORDER; BLADDER CRAMP; BLADDER DYSFUNCTION; CATATONIA; CLINICAL COMPETENCE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; COMPETITIVE INHIBITION; CONSENSUS DEVELOPMENT; DISSOCIATIVE DISORDER; DRUG APPROVAL; DRUG COST; DRUG DEPENDENCE; DRUG EFFICACY; DRUG FORMULARY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERANCE; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; HALLUCINATION; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; ILLUSION; INFORMED CONSENT; LONG TERM CARE; MAJOR DEPRESSION; MEDICAL ETHICS; MENTAL DISEASE; MONOTHERAPY; OFF LABEL DRUG USE; OUTPATIENT CARE; PARANOIA; PATIENT MONITORING; PATIENT SAFETY; PSYCHOSOMATIC DISORDER; RECOGNITION; RESEARCH ETHICS; REVIEW; REWARD; RISK BENEFIT ANALYSIS; SHORT TERM MEMORY; TREATMENT RESISTANT DEPRESSION; WORKING MEMORY; ANTAGONISTS AND INHIBITORS; DEPRESSIVE DISORDER, MAJOR; ETHICS; STANDARDS;

DEPRESSIVE DISORDER, MAJOR; HUMANS; KETAMINE; OFF-LABEL USE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84912571810     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-014-0527-z     Document Type: Review

References (17)

1. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–4. doi:10.1016/S0006-3223(99)00230-9.
2. Li N, Lee B, Liu R-J, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–64.
3. Stix G. From club to clinic: physicians push off-label ketamine as rapid depression treatment, part 1. Scientific American. 2013. This article provides a thorough overview of the current issues and controversies involved in using ketamine as a treatment for major depressive disorder.
4. Department of Justice. Intelligence bulletin: ketamine. 2004(2004-L0424-007).
5. Murrough JW, Wan L-B, Iacoviello B, Collins KA, Solon C, Glicksberg B, et al. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology. 2014;23(3):481–8. doi:10.1007/s00213-013-3255-x. This study examined neurocognitive performance in depressed patients and found that patients who responded to ketamine 24 h following treatment had poorer baseline neurocognitive performance than nonresponders.
6. Carter LP, Kleykamp BA, Griffiths RR, Mintzer MZ. Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers. Psychopharmacology. 2013;226(1):53–63.
7. Loo CK, Katalinic N, Garfield JBB, Sainsbury K, Hadzi-Pavlovic D, Mac-Pherson R. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. J Affect Disord. 2012;142(1–3):233–40. doi:10.1016/j.jad.2012.04.032.
8. McDaniel WW, Sahota AK, Vyas BV, Laguerta N, Hategan L, Oswald J. Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies. J ECT. 2006;22(2):103–6.
9. Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction. 2010;105(1):121–33.
10. Reier CE. Ketamine—“dissociative agent” or hallucinogen? N Engl J Med. 1971;284(14):791–2.
11. Green SM, Krauss B. The semantics of ketamine. Ann Emerg Med. 2000;36(5):480–2.
12. Muetzelfeldt L, Kamboj S, Rees H, Taylor J, Morgan C, Curran H. Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008;95(3):219–29.
13. Jeste DV, Saks E. Decisional capacity in mental illness and substance use disorders: empirical database and policy implications. Behav Sci Law. 2006;24(4):607–28.
14. Appelbaum PS, Grisso T, Frank E, O’Donnell S, Kupfer DJ. Competence of depressed patients for consent to research. Am J Psychiatr. 1999;156(9):1380–4.
15. Depression Recovery Centers. Prospective Patients. 2014. http://depressionrecoverycenters.com/prospective-patients/.
16. Lorant V, Deliège D, Eaton W, Robert A, Philippot P, Ansseau M. Socioeconomic inequalities in depression: a meta-analysis. Am J Epidemiol. 2003;157(2):98–112.
17. Schatzberg AF. A word to the wise about ketamine. Am J Psychiatr. 2014;171(3):262–4. A review of concerns surrounding the administration of ketamine for major depressive disorder concludes with the argument that until more is known about its effects and risks, “clinicians should be wary about embarking on a slippery ketamine slope.”.